Medical/Pharmaceuticals
ThinkCyte Secures $32 million in Series C Funding to Drive Global Expansion of VisionSort™
TOKYO and REDWOOD CITY, Calif., Aug. 31, 2024 /PRNewswire/ -- ThinkCyte today announced the successful completion of its Series C funding round. Including the equity financingsecured last November, the company raised an additional $15 million in the extension round, bringing the total to $32 mill...
2024-08-31 00:30
5073
LifeTech Scientific Corporation Announced 2024 Interim Results: International Business Increased by 30%, Net Profit Margin Attributable to Owners of the Company Reached 35.8%
SHENZHEN, China, Aug. 30, 2024 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiarie...
2024-08-30 20:48
7161
Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation
* European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients.[1-3] The safety profil...
2024-08-30 20:44
4127
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted theChina rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasi...
2024-08-30 19:34
5624
Breaking News | Sanyou Bio Launches Comprehensive Monkeypox Product Line
SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of a comprehensive product line targeting monkeypox, which includes antigens, monoclonal antibodies, and overexpression cell lines. This product line features 65 items ...
2024-08-30 18:00
2562
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations
* Guardant360® CDx is the first blood-based companion diagnostic to be approved inJapan for the detection of EGFR exon 20 insertion mutations TOKYO, Aug. 30, 2024 /PRNewswire/ -- Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo / Representative Director:Mika Takaki), a leading precision oncolog...
2024-08-30 11:01
3578
/DISREGARD RELEASE: Celltrion USA/
We are advised by Celltrion USA that journalists and other readers should disregard the news release, CelltrionUSA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit ...
2024-08-30 08:35
1802
CARsgen® Announces 2024 Interim Results
SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced its 2024 Interim Results. Business Highlights * Zevor-cel was...
2024-08-29 20:50
3461
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS net profit reached RMB168.2 million, increased by 15.1% YoY HONG KONG, Aug. 29, 2024 /PRNewswire/ ...
2024-08-29 20:42
3809
Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts
BOSTON, Aug. 29, 2024 /PRNewswire/ -- In August 2024, Medicilon USA Corp (Medicilon) officially commenced operations at its second R&D center in Massachusetts, USA. Research at the new facility will focus on animal models for PK/PD and toxicology studies. This milestone heralds Medicilon's continu...
2024-08-29 20:30
1203
UTime Initiates Financial and Legal Due Diligence on Bowen Therapeutics
SHENZHEN, China, Aug. 29, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO
2024-08-29 20:30
2542
ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions
Showcasing at ESCRS from Sept. 6 to 10, in Barcelona, Spain: REFRACTIVE INDUSTRY MILESTONES: ZEISS extends its global refractive industry momentum with more than 10 million eyes treated with ZEISS SMILE and ZEISS SMILE pro; ZEISS announces first treatment in the CE market for hyperopia with len...
2024-08-29 20:00
1654
Discover the Top 6 Highlights of Medtec 2024 and Explore the Latest Industry Trends
SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- The 18th International Medical Device Design and Manufacturing Technology Exhibition (Medtec 2024) will be held at the Shanghai World Expo Exhibition and Convention Center fromSeptember 25th to 27th. This year's event will cover 42,000+㎡and feature over 1,0...
2024-08-29 17:00
2380
Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
2024 Interim Result Highlights (For the six months ended June 30, 2024) * Company published the efficacy and safety data of Cohort-G of TranStar102 study for osemitamab (TST001), plus checkpoint inhibitor and CAPOX as the first-line treatment of patients with locally advanced or metastatic G/GE...
2024-08-29 14:31
2659
Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan
BENGALURU, India, Aug. 29, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., Janss...
2024-08-29 13:38
1633
Smartee Hosts Breakthrough GS Mandibular Repositioning Therapy Conference in Singapore
SINGAPORE, Aug. 29, 2024 /PRNewswire/ -- Smartee organized the GS Mandibular
Repositioning Therapy Conference inSingapore, gathering top dental
professionals from acrossSingapore, Australia, Malaysia, and the Philippines.
2024-08-29 12:47
8660
LOTTE Holdings establishes a new Healthcare and Biopharmaceutical Corporate Venture Capital
TOKYO, Aug. 29, 2024 /PRNewswire/ -- LOTTE Holdings Co., Ltd. ("LOTTE
Holdings") is pleased to announce the establishment of a new Healthcare and
Biopharmaceutical Corporate Venture Capital ("CVC") dedicated to investing in
biopharmaceuticals and next-generation modalities.
2024-08-29 10:00
1988
Necessary Care or Abuse? Unpacking the Reason Behind Overprescription
SINGAPORE, Aug. 29, 2024 /PRNewswire/ -- Have you ever wondered if the ten prescriptions your doctor gave you for a cold are truly necessary? Or is there a more complex issue of abuse happening behind the scenes? Today's Case: Overcharging a 7-Year-Old Somsak (an alias name), a 7-year-old boy fr...
2024-08-29 08:30
2452
Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024
SAN FRANCISCO and SUZHOU, China, Aug. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-08-29 08:00
1833
Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization
* Approval of ivonescimab for 2L+ EGFRm NSCL; HARMONi-A is the only phase III study that demonstrates significant benefit across all subgroups for PFS, and is also the only study to achieve the primary endpoint while showing a positive trend in OS benefit; HARMONi-A study presented in an oral p...
2024-08-29 04:20
2328
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5214
